ICRM
ENTA icon

Insight Capital Research & Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Insight Capital Research & Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-127,507
Closed -$6.48M – 121
2014
Q4 		$6.48M Sell
127,507
-9,130
-7% -$409K 1.66% 9
2014
Q3 		$5.41M Sell
136,637
-21,678
-14% -$864K 1.41% 22
2014
Q2 		$6.82M Sell
158,315
-48,548
-23% -$1.85M 1.56% 20
2014
Q1 		$8.27M Buy
+206,863
New +$7.51M 1.91% 7

Other funds holding ENTA

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MVM
McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Insight Capital Research & Management's ENTA Position: Q1 2015 in Review

Insight Capital Research & Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2015, closing a stake of 127,507 shares — an estimated $6.48M sold.

Insight Capital Research & Management first reported a position in ENTA in Q1 2014 and held it in 4 quarters. The position peaked at $8.27M in Q1 2014. 117 funds tracked by Wall St. Rank hold ENTA as of Q1 2015.

  • Insight Capital Research & Management reported no remaining Enanta Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Insight Capital Research & Management sold 127,507 Enanta Pharmaceuticals shares in Q1 2015, an estimated $6.48M.
  • Insight Capital Research & Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 4 quarters.
  • Insight Capital Research & Management's Enanta Pharmaceuticals position peaked at $8.27M in Q1 2014.
  • 117 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2015.

Based on Insight Capital Research & Management's 13F filing for Q1 2015, filed 7 May 2015.